市場調查報告書

麻醉劑的全球市場:成長率,趨勢及預測(2019年∼2024年)

Anesthesia Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 390890
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
麻醉劑的全球市場:成長率,趨勢及預測(2019年∼2024年) Anesthesia Drugs Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 112 Pages
簡介

全球麻醉劑市場預計2018年達到45億1,211萬美元的規模,2024年達到53億1,466萬美元,預計從2019年到2024年這段預測期間內,將以4.20%的年複合成長率成長。促進該市場的成長的主要原因,有手術數的增加和麻醉劑的新核准等。

本報告提供全球麻醉劑市場調查,整體市場趨勢,各藥物種類、給藥途徑、應用、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等資訊總括性彙整。

目錄

第1章 簡介

  • 調查的成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 手術數的增加
    • 麻醉劑的新核准
    • 新發明的醫藥品的降低成本
  • 市場阻礙因素
    • 一般麻醉劑的副作用
    • 熟練的麻醉科醫生不足
    • 法規的問題
  • 波特的五力分析
    • 新加入廠商的威脅
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 賣主談判力
    • 替代產品的威脅
    • 產業內的競爭激烈度

第5章 市場區隔

  • 各藥物類型
    • 一般麻醉劑
    • 局部麻醉劑
  • 各給藥途徑
    • 吸入
    • 注射
    • 其他給藥途徑
  • 各應用領域
    • 一般外科
    • 整形外科
    • 美容整形
    • 牙科手術
    • 其他應用
  • 地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Baxter
    • Hospira
    • Abbott Laboratories
    • AstraZeneca
    • F. Hoffmann-La Roche AG
    • B. Braun Melsungen AG
    • AbbVie Inc.
    • Boehringer Ingelheim International GmbH
    • Eisai
    • Fresenius SE & Co. KGaA

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 53145

The anesthesia drugs market was valued at USD 4,512.11 million in 2018, and is estimated to be valued at USD 5,314.66 million in 2024, while witnessing a CAGR of 4.20% over the forecast period of 2019-2024. The key factors propelling the growth of this market are the increasing number of surgeries and new approvals of anesthetic drugs.

There are wide ranges of surgeries based on the length of stay for surgeries. These include elective surgery and emergency surgery. Based on procedures, there are wide ranges of surgeries, where open surgery is most common. Others include keyhole surgery, laparoscopic surgery, microsurgery, and cosmetic surgery. In recent years, several articles have reported a significant rise in the number of day care procedures (ambulatory surgery), and diagnostic and therapeutic services. This is primarily due to the increased dependence on advances made in anesthesia, surgical, and medical technologies.

Furthermore, the rise in surgeries is attributed to the increasing risk of various accidents, sports injuries, and diseases, globally. According to the Center of Disease Control and Prevention (CDC), more than 51 million inpatient surgeries and 53 million outpatient surgeries were performed in the United States in 2017. In the European region, in England, nearly 4.7 million patients were admitted for surgeries in 2014, as per the Royal College of Surgeons. This indicates the rising number of surgeries, which ultimately results into the rising demand for the anesthesia drugs and propels the growth of the anesthesia drugs market.

Key Market Trends

Propofol Sub-segment is Expected to Show the Fastest Growth in the General Anesthesia Drugs Segment

The propofol sub-segment of the anesthesia drugs market is expected to experience a fast growth rate while witnessing a CAGR of 4.20% over the forecast period.

Propofol is a drug that has been used for a long time for various surgical procedures requiring anesthesia. Teva Pharmaceuticals had stopped manufacturing propofol for a particular time; however, the drug returned to the market in 2013. Hospira is another major player in the propofol sub-segment. In 2015, Pfizer acquired Hospira and created a leading global established pharmaceutical (GEP) business. Some of the companies who manufacture propofol injections are Neon Laboratories Limited, Bharat Serums and Vaccines Limited, and Fresenius Kabi. The drug is always in demand in the market for utilization in different surgeries, and is expected to witness rapid growth in the coming years.

North America Dominates the Market and is Expected to Follow the Same Trend Over the Forecast Period

North America currently dominates the anesthesia drugs market and is expected to continue its stronghold for a few more years. The US anesthesia market is the largest regional market in the world. This market is driven by factors, such as the increasing number of surgeries, rising aging population with increasing chronic conditions, and advancements in anesthesia technologies.

Competitive Landscape

The anesthesia drugs market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with rising drug approvals, mid-size to smaller companies are increasing their market presence by introducing new ingredients with fewer prices. Companies, like Baxter, Abbott Laboratories, AstraZeneca, Roche Holding AG, and B. Braun Melsungen AG, hold substantial market shares in the anesthesia drugs market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Number of Surgeries
    • 4.2.2 New Approvals of Anesthetic Drugs
    • 4.2.3 Reduction in the Cost of Newly Invented Drugs
  • 4.3 Market Restraints
    • 4.3.1 Side Effects of General Anesthetics
    • 4.3.2 Lack of Skilled-Anesthetics
    • 4.3.3 Regulatory Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Type
    • 5.1.1 General Anesthesia Drugs
      • 5.1.1.1 Propofol
      • 5.1.1.2 Sevoflurane
      • 5.1.1.3 Desflurane
      • 5.1.1.4 Dexmedetomidine
      • 5.1.1.5 Remifentanil
      • 5.1.1.6 Midazolam
      • 5.1.1.7 Other General Anesthesia Drugs
    • 5.1.2 Local Anesthesia Drugs
      • 5.1.2.1 Bupivacaine
      • 5.1.2.2 Ropivacaine
      • 5.1.2.3 Lidocaine
      • 5.1.2.4 Chloroprocaine
      • 5.1.2.5 Articaine
      • 5.1.2.6 Benzocaine
      • 5.1.2.7 Local Anesthesia Drugs
  • 5.2 By Route of Administration
    • 5.2.1 Inhalation
    • 5.2.2 Injection
    • 5.2.3 Other Routes of Administration
  • 5.3 By Application
    • 5.3.1 General Surgeries
    • 5.3.2 Plastic Surgery
    • 5.3.3 Cosmetic Surgeries
    • 5.3.4 Dental Surgeries
    • 5.3.5 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Baxter
    • 6.1.2 Hospira
    • 6.1.3 Abbott Laboratories
    • 6.1.4 AstraZeneca
    • 6.1.5 F. Hoffmann-La Roche AG
    • 6.1.6 B. Braun Melsungen AG
    • 6.1.7 AbbVie Inc.
    • 6.1.8 Boehringer Ingelheim International GmbH
    • 6.1.9 Eisai Co. Ltd
    • 6.1.10 Fresenius SE & Co. KGaA

7 MARKET OPPORTUNITIES AND FUTURE TRENDS